Literature DB >> 24944547

A SPECIAL MEETING REVIEW EDITION: Updates in the Treatment of Hepatitis C Virus Infection From EASL 2012: The 47th Annual Meeting of the European Association for the Study of the LiverApril 18-22, 2012 • Barcelona, SpainSpecial Reporting on:• Safety of Telaprevir or Boceprevir in Combination with Peginterferon α/Ribavirin in Cirrhotic Nonresponders. First Results of the French Early Access Program (ANRS C020-CUPIC)• SVR in Prior Peginterferon/Ribavirin (PR) Treatment Failures After Re-treatment with Boceprevir + PR: The PROVIDE Study Interim Results• Futility Rules in Telaprevir Combination Treatment• Boceprevir Plus Peginterferon/Ribavirin for the Treatment of HCV/HIV Co-Infected Patients: End-of-Treatment (Week 48) Interim ResultsPLUS Meeting Abstract Summaries With Expert Commentary by: Jean-Pierre Bronowicki, MD, PhDDepartment of Hépato-GastroenterologieCentre Hospitalier Universitaire de Nancy-BraboisVandoeuvre-lès-Nancy, France.

.   

Abstract

Entities:  

Year:  2012        PMID： 24944547      PMCID： PMC4017917     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  7 in total

1.  Boceprevir for previously treated chronic HCV genotype 1 infection.

Authors:  Bruce R Bacon; Stuart C Gordon; Eric Lawitz; Patrick Marcellin; John M Vierling; Stefan Zeuzem; Fred Poordad; Zachary D Goodman; Heather L Sings; Navdeep Boparai; Margaret Burroughs; Clifford A Brass; Janice K Albrecht; Rafael Esteban
Journal:  N Engl J Med       Date:  2011-03-31       Impact factor: 91.245

2.  Response-guided telaprevir combination treatment for hepatitis C virus infection.

Authors:  Kenneth E Sherman; Steven L Flamm; Nezam H Afdhal; David R Nelson; Mark S Sulkowski; Gregory T Everson; Michael W Fried; Michael Adler; Hendrik W Reesink; Marie Martin; Abdul J Sankoh; Nathalie Adda; Robert S Kauffman; Shelley George; Christopher I Wright; Fred Poordad
Journal:  N Engl J Med       Date:  2011-09-15       Impact factor: 91.245

3.  Telaprevir for retreatment of HCV infection.

Authors:  Stefan Zeuzem; Pietro Andreone; Stanislas Pol; Eric Lawitz; Moises Diago; Stuart Roberts; Roberto Focaccia; Zobair Younossi; Graham R Foster; Andrzej Horban; Peter Ferenci; Frederik Nevens; Beat Müllhaupt; Paul Pockros; Ruben Terg; Daniel Shouval; Bart van Hoek; Ola Weiland; Rolf Van Heeswijk; Sandra De Meyer; Don Luo; Griet Boogaerts; Ramon Polo; Gaston Picchio; Maria Beumont
Journal:  N Engl J Med       Date:  2011-06-23       Impact factor: 91.245

4.  Telaprevir for previously untreated chronic hepatitis C virus infection.

Authors:  Ira M Jacobson; John G McHutchison; Geoffrey Dusheiko; Adrian M Di Bisceglie; K Rajender Reddy; Natalie H Bzowej; Patrick Marcellin; Andrew J Muir; Peter Ferenci; Robert Flisiak; Jacob George; Mario Rizzetto; Daniel Shouval; Ricard Sola; Ruben A Terg; Eric M Yoshida; Nathalie Adda; Leif Bengtsson; Abdul J Sankoh; Tara L Kieffer; Shelley George; Robert S Kauffman; Stefan Zeuzem
Journal:  N Engl J Med       Date:  2011-06-23       Impact factor: 91.245

5.  Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections.

Authors:  Graham R Foster; Christophe Hézode; Jean-Pierre Bronowicki; Giampiero Carosi; Ola Weiland; Lieselotte Verlinden; Rolf van Heeswijk; Ben van Baelen; Gaston Picchio; Maria Beumont
Journal:  Gastroenterology       Date:  2011-05-31       Impact factor: 22.682

6.  Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3.

Authors:  Marcelo O Silva; Michelle Treitel; Donald J Graham; Stephanie Curry; Maria J Frontera; Patricia McMonagle; Samir Gupta; Eric Hughes; Robert Chase; Fred Lahser; Richard J O Barnard; Anita Y M Howe; John A Howe
Journal:  J Hepatol       Date:  2013-02-27       Impact factor: 25.083

7.  A SPECIAL MEETING REVIEW EDITION: Updates in the Treatment of Hepatitis C Virus Infection From EASL 2012: The 47th Annual Meeting of the European Association for the Study of the LiverApril 18-22, 2012 • Barcelona, SpainSpecial Reporting on:• Safety of Telaprevir or Boceprevir in Combination with Peginterferon α/Ribavirin in Cirrhotic Nonresponders. First Results of the French Early Access Program (ANRS C020-CUPIC)• SVR in Prior Peginterferon/Ribavirin (PR) Treatment Failures After Re-treatment with Boceprevir + PR: The PROVIDE Study Interim Results• Futility Rules in Telaprevir Combination Treatment• Boceprevir Plus Peginterferon/Ribavirin for the Treatment of HCV/HIV Co-Infected Patients: End-of-Treatment (Week 48) Interim ResultsPLUS Meeting Abstract Summaries With Expert Commentary by: Jean-Pierre Bronowicki, MD, PhDDepartment of Hépato-GastroenterologieCentre Hospitalier Universitaire de Nancy-BraboisVandoeuvre-lès-Nancy, France.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-06
  7 in total
  21 in total

1.  A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2013: The 48th Annual Meeting of the European Association for the Study of the LiverApril 24-28, 2013 • Amsterdam, The NetherlandsSpecial Reporting on:• Simeprevir Plus Peginterferon/Ribavirin Is Associated with a High SVR12 Rate in Treatment-Naive Patients with Genotype 1 Hepatitis C Virus Infection• Addition of Simeprevir to Peginterferon/Ribavirin Is Associated with Faster Resolution of Fatigue in Treatment-Naive Patients• Sofosbuvir Plus Ribavirin Demonstrates Significant Efficacy in Multiple HCV Genotype 2/3 Populations• Daclatasvir Plus Sofosbuvir with or without Ribavirin Yields 100% SVR24 Rate in Genotype 1 Patients Who Fail Telaprevir or Boceprevir• Addition of TG4040 Vaccine to Peginterferon/Ribavirin Increases Sustained Virologic Response Rate at 24 Weeks in Genotype 1 Hepatitis C InfectionPLUS Meeting Abstract Summaries With Expert Commentary by: Ira M. Jacobson, MDJoan Sanford I. Weill Medical College at Cornell UniversityNew York, New York.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-06

Review 2.  Direct-acting antiviral agents for hepatitis C virus infection.

Authors:  Jennifer J Kiser; Charles Flexner
Journal:  Annu Rev Pharmacol Toxicol       Date:  2012-11-05       Impact factor: 13.820

Review 3.  Interferon-free hepatitis C therapy: how close are we?

Authors:  Paul J Pockros
Journal:  Drugs       Date:  2012-10-01       Impact factor: 9.546

Review 4.  Novel therapies for hepatitis C - one pill fits all?

Authors:  Michael P Manns; Thomas von Hahn
Journal:  Nat Rev Drug Discov       Date:  2013-06-28       Impact factor: 84.694

Review 5.  Treatment decisions and contemporary versus pending treatments for hepatitis C.

Authors:  Paul M Trembling; Sudeep Tanwar; William M Rosenberg; Geoffrey M Dusheiko
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-09-10       Impact factor: 46.802

Review 6.  Oral antiviral therapies for chronic hepatitis C infection.

Authors:  Stanislas Pol; Marion Corouge; Philippe Sogni
Journal:  Ther Adv Infect Dis       Date:  2013-06

Review 7.  Boceprevir: a review of its use in the management of chronic hepatitis C genotype 1 infection.

Authors:  Karly P Garnock-Jones
Journal:  Drugs       Date:  2012-12-24       Impact factor: 9.546

8.  Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.

Authors:  Jagpreet Chhatwal; Shannon A Ferrante; Cliff Brass; Antoine C El Khoury; Margaret Burroughs; Bruce Bacon; Rafael Esteban-Mur; Elamin H Elbasha
Journal:  Value Health       Date:  2013 Sep-Oct       Impact factor: 5.725

Review 9.  Current and future therapies for hepatitis C virus infection.

Authors:  T Jake Liang; Marc G Ghany
Journal:  N Engl J Med       Date:  2013-05-16       Impact factor: 91.245

10.  The changing burden of hepatitis C virus infection in the United States: model-based predictions.

Authors:  Mina Kabiri; Alison B Jazwinski; Mark S Roberts; Andrew J Schaefer; Jagpreet Chhatwal
Journal:  Ann Intern Med       Date:  2014-08-05       Impact factor: 25.391
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.